FDA Approves Ivosidenib for Advanced/Metastatic Cholangiocarcinoma

The FDA has granted approval to ivosidenib (Tibsovo®, Servier Pharmaceuticals) for patients with previously treated, locally advanced, or metastatic cholangiocarcinoma that has an isocitrate dehydrogenase-1 (IDH1) mutation. In addition, the FDA approved the Oncomine™ Dx Target Test (Life Technologies Corporation) as a companion diagnostic device to determine eligibility for treatment with ivosidenib. "Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahe...
Continue reading

Recent Advances in T-Cell Lymphoma: A Video Interview With Dr. Steven Horwitz

In this interview, Steven Horwitz, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, speaks with Oncology Data Advisor about the recent advancements in the treatment of T-cell lymphoma. Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Steven Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center. Keira Smith: What do you consider some of the ...
Continue reading

FDA Approves Lenvatinib and Pembrolizumab Combination for Advanced Renal Cell Carcinoma

The FDA has granted approval to the combination of lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for the treatment of patients with advanced renal cell carcinoma (RCC) who are undergoing first-line treatment. "Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced RCC," wrote Robert Motzer, MD, Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center, and colleagues, in their publication of results of the p...
Continue reading

FDA Grants Regular Approval to Pembrolizumab/Lenvatinib Combination for Endometrial Carcinoma

The FDA has granted regular approval to pembrolizumab (Keytruda®, Merck), in combination with lenvatinib, (Lenvima®, Eisai), for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Prior to this regular approval, the FDA granted accelerated approval to the pembrolizumab/lenvatinib co...
Continue reading

Acupuncture for Managing Chronic Musculoskeletal Pain in Cancer Survivors: Jun Mao, MD, MSCE

Nearly 50% of cancer survivors are undertreated for chronic pain, a condition which negatively impacts cancer-related outcomes, physical function, and quality of life. Due to the challenges of the opioid crisis, non-pharmacologic alternatives for pain management in cancer survivors are greatly needed. In the randomized PEACE trial, results of which were recently published in JAMA Oncology, investigators found that patients receiving electroacupuncture and auricular acupuncture experienced signif...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.